Dr. Carlos D. Malvestutto, MD

Dr. Malvestutto practices at Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center.

Dr. Malvestutto's NPI, 1548466022, was assigned on June 22, 2007. Dr. Malvestutto holds Ohio license 35124239.

Dr. Malvestutto's primary practice is Ohio State University Hospital, at 410 West 10th Avenue, Columbus, OH 43210 in Franklin County. The practice phone is (614) 293-9700.

Dr. Malvestutto's primary practice is Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center. Dr. Malvestutto is also affiliated with The James Cancer Hospital and Solove Research Institute. The medical group on file is Ohio State University Physicians. Dmand AI also links Dr. Malvestutto to 1 more hospital, 2 hospital outpatient departments and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Malvestutto practices, 5 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Malvestutto's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Malvestutto is licensed in Ohio.

CMS data shows 136 Medicare services from Dr. Malvestutto across 6 procedure codes in 2024, for 88 Medicare patients. Medicare paid $11,303 for them.

CMS counts 88 Medicare patients who saw Dr. Malvestutto in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high blood pressure, and 61% have high cholesterol. 34% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Malvestutto's median patient age at 57, with 31% women.

In 2024, Dr. Malvestutto wrote 1,294 Medicare Part D claims for 79 patients. CMS names the drug for 1,042 of them, across 26 drugs with 11 or more claims each, at $2,758,262 in total drug cost. In 2023, CMS named 933 claims across 23 drugs.

Dr. Malvestutto accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Malvestutto as offering telehealth.

Dmand AI links 42 papers to Dr. Malvestutto, published from 2015 to 2025. 2022 was the busiest year, with 6. The most frequent topics are HIV Infections, Cardiovascular Diseases and Anti-HIV Agents. Dr. Malvestutto has published most often in AIDS. Dr. Malvestutto's most frequent co-authors are Judith Ann Aberg, MD, Carl Jack Fichtenbaum, MD and Markella V. Zanni, MD.

Dmand AI links Dr. Malvestutto to 3 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include HIV Infections, Lentivirus Infections and COVID-19. Open Payments lists research payments to Dr. Malvestutto that name 1 trial.

CMS Open Payments shows 93 general payments to Dr. Malvestutto from 5 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 89% of the total. ViiV Healthcare Company paid the most, $52,464. It also lists 1 research payment totaling $34,157 in 2020, naming 1 clinical trial.